ASCO - Endocyte Officials to Present Results from Four Clinical Trials at ASCO Annual Meeting - PRECEDENT = EC145/platinum resistant ovarian

"Interim results from the PRECEDENT study, a randomized phase II study of the combination of EC145 and Doxil for the treatment of patients with platinum-resistant ovarian cancer, will be provided during an oral presentation. EC145 is a folate-targeted conjugate of a very potent chemotherapy drug."